Jaime R Merchan
University of Miami
H-index: 35
North America-United States
Top articles of Jaime R Merchan
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract CT182: Oncolytic virus CF33-hNIS for the treatment of advanced cancer | Cancer Research | Daneng Li Anthony F Shields Hirva Mamdani Patrick Travis Gavin Wright | 2024/4/5 |
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab | Christopher J Hoimes Thomas W Flaig Matthew I Milowsky Terence W Friedlander Mehmet Asim Bilen | 2024/3/1 | |
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study | Journal of Clinical Oncology | Robert J Motzer Camillo Porta Masatoshi Eto Thomas Powles Viktor Grünwald | 2024/1 |
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: extended 41-month follow-up in the clear cell renal cell carcinoma cohort | European Journal of Cancer | Eric Jonasch Todd M Bauer Kyriakos P Papadopoulos Elizabeth R Plimack Jaime R Merchan | 2024/1/1 |
Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer | Journal of clinical oncology | Christopher J Hoimes Thomas W Flaig Matthew I Milowsky Terence W Friedlander Mehmet Asim Bilen | 2023/1/1 |
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised … | The Lancet Oncology | Toni K Choueiri Masatoshi Eto Robert Motzer Ugo De Giorgi Tomas Buchler | 2023/3/1 |
AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK | PLoS computational biology | Derek J Essegian Valery Chavez Rabia Khurshid Jaime R Merchan Stephan C Schürer | 2023/5/26 |
Abstract C024: Trial in progress: Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors | Molecular Cancer Therapeutics | Shivaani Kummar Minal Barve Eric Feldman Seunghyun Ma Jaime Merchan | 2023/12/1 |
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+ P) vs sunitinib (S) in patients (pts) with advanced renal cell … | Robert J Motzer Camillo Porta Masatoshi Eto Thomas Powles Viktor Grünwald | 2023/6/1 | |
Характеристики и методы лечения основных нежелательных явлений у пациентов с распространенным почечно-клеточным раком, получающих терапию комбинацией ленватиниба с … | Онкоурология | R Motzer S George JR Merchan TE Hutson X Song | 2023 |
Correction: AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK | PLoS computational biology | Derek J Essegian Valery Chavez Rabia Khurshid Jaime R Merchan Stephan C Schürer | 2023/11/22 |
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study | The Lancet Oncology | Toni K Choueiri David F McDermott Jaime Merchan Todd M Bauer Robert Figlin | 2023/5/1 |
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin+ pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial … | Shilpa Gupta Jonathan E Rosenberg Rana R McKay Thomas W Flaig Daniel P Petrylak | 2023/6/1 | |
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in … | Journal for immunotherapy of cancer | Charles M Rudin Hardev S Pandha Matthew Zibelman Wallace L Akerley Kevin J Harrington | 2023 |
1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell … | Annals of Oncology | SY Rha WK Bae C Kim SY Oh HW Lee | 2023/10/1 |
Clinical-pathological features and treatment outcomes in Hispanic/Latino patients with advanced renal cell carcinoma at a single institution. | Jesus Antonio Ocejo Gallegos Abner Murray Sandra Jones Rosa Lizeth Frias Jose Noy | 2023/6/1 | |
Targeting immunosuppressive adenosine to enhance vaccinia virus renal cancer oncolysis in vivo | Cancer Research | Valery A Chavez Floritza Bustamante Carolina Merchan-Mendes Shannon Saigh Patricia Guevara | 2023/4/4 |
Epidemiological characterization of renal cell carcinoma in Hispanics: A single US center cohort study | Cancer Research | Abner A Murray Jesus A Ocejo Gallegos Sandra Jones Jose Noy Rosa L Frias | 2023/4/4 |
Abstract C121: Epidemiological characteristics and patterns of recurrence of renal cell carcinoma in Hispanics: A single US center cohort study | Abner Antonio Murray Melo Jesus Antonio Ocejo Gallegos Jaime Rafael Merchan | 2023/1/1 | |
LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC) | Annals of Oncology | TK Choueiri T Bauer JR Merchan DF McDermott R Figlin | 2023/10/1 |
